ATE439357T1 - Indolylderivate als liver-x-rezeptormodulatoren - Google Patents

Indolylderivate als liver-x-rezeptormodulatoren

Info

Publication number: ATE439357T1
Authority: AT; Austria
Prior art keywords: liver; receptor modulators; indolyl derivatives; indolyl; derivatives
Prior art date: 2004-05-03

Application number

AT05751959T

Other languages

English (en)

Inventor

Henrietta Dehmlow

Bernd Kuhn

Narendra Panday

Hasane Ratni

Tanja Schulz-Gasch

Matthew Wright

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-05-03

Filing date

2005-04-26

Publication date

2009-08-15

2005-04-26 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2009-08-15 Application granted granted Critical

2009-08-15 Publication of ATE439357T1 publication Critical patent/ATE439357T1/de

Links

-1 INDOLYL Chemical class 0.000 title 1
102000004311 liver X receptors Human genes 0.000 title 1
108090000865 liver X receptors Proteins 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Vascular Medicine (AREA)
Oncology (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Psychiatry (AREA)
Communicable Diseases (AREA)
Emergency Medicine (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Indole Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT05751959T 2004-05-03 2005-04-26 Indolylderivate als liver-x-rezeptormodulatoren ATE439357T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP04101889		2004-05-03
PCT/EP2005/004454 WO2005105791A1 (en)	2004-05-03	2005-04-26	Indolyl derivatives as liver-x-receptor modulators

Publications (1)

Publication Number	Publication Date
ATE439357T1 true ATE439357T1 (de)	2009-08-15

Family

ID=34970495

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05751959T ATE439357T1 (de)	2004-05-03	2005-04-26	Indolylderivate als liver-x-rezeptormodulatoren

Country Status (26)

Country	Link
US (2)	US7173048B2 (de)
EP (1)	EP1756096B1 (de)
JP (1)	JP4682192B2 (de)
KR (1)	KR100893449B1 (de)
CN (1)	CN1950365A (de)
AR (1)	AR049497A1 (de)
AT (1)	ATE439357T1 (de)
AU (1)	AU2005238176B2 (de)
BR (1)	BRPI0510599A (de)
CA (1)	CA2564563C (de)
DE (1)	DE602005015962D1 (de)
DK (1)	DK1756096T3 (de)
ES (1)	ES2329489T3 (de)
HR (1)	HRP20090533T1 (de)
IL (1)	IL178767A0 (de)
MX (1)	MXPA06012683A (de)
MY (1)	MY139571A (de)
NO (1)	NO20065503L (de)
NZ (1)	NZ550447A (de)
PL (1)	PL1756096T3 (de)
PT (1)	PT1756096E (de)
RU (1)	RU2368612C2 (de)
SI (1)	SI1756096T1 (de)
TW (1)	TWI287537B (de)
WO (1)	WO2005105791A1 (de)
ZA (1)	ZA200608886B (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7790745B2 (en)	2005-10-21	2010-09-07	Bristol-Myers Squibb Company	Tetrahydroisoquinoline LXR Modulators
US7741317B2 (en)	2005-10-21	2010-06-22	Bristol-Myers Squibb Company	LXR modulators
US20070244128A1 (en) *	2005-11-04	2007-10-18	Amira Pharmaceuticals, Inc.	5-lipoxygenase-activating protein (flap) inhibitors
GB2431927B (en) *	2005-11-04	2010-03-17	Amira Pharmaceuticals Inc	5-Lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) *	2005-11-04	2011-07-12	Amira Pharmaceuticals, Inc.	5-lipdxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en) *	2005-11-04	2013-03-19	Panmira Pharmaceuticals, Llc	5-lipoxygenase-activating protein (FLAP) inhibitors
US20070225285A1 (en) *	2005-11-04	2007-09-27	Amira Pharmaceuticals, Inc.	5-lipoxygenase-activating protein (flap) inhibitors
US20070219206A1 (en) *	2005-11-04	2007-09-20	Amira Pharmaceuticals, Inc.	5-lipoxygenase-activating protein (flap) inhibitors
CA2660570C (en)	2006-08-24	2016-08-09	University Of Tennessee Research Foundation	Substituted acylanilides and methods of use thereof
ES2452343T3 (es) *	2006-09-29	2014-04-01	Glaxosmithkline Llc	Compuestos de indol sustituidos
US8404896B2 (en)	2006-12-01	2013-03-26	Bristol-Myers Squibb Company	N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases
PE20090213A1 (es)	2007-05-04	2009-02-28	Bristol Myers Squibb Co	Agonistas del receptor acoplado a la proteina g gpr119 [6,5]-biciclicos
WO2008137435A1 (en) *	2007-05-04	2008-11-13	Bristol-Myers Squibb Company	[6,6] and [6,7]-bicyclic gpr119 g protein-coupled receptor agonists
EA018709B1 (ru) *	2007-07-17	2013-10-30	Бристол-Маерс Сквибб Компани	Пиридоновые агонисты сопряженного с g-белком рецептора gpr119
KR100918814B1 (ko) *	2007-10-04	2009-09-25	건국대학교 산학협력단	인쇄방법을 이용한 세라믹 전자부품 고속제조방법
TW200920369A (en) *	2007-10-26	2009-05-16	Amira Pharmaceuticals Inc	5-lipoxygenase activating protein (flap) inhibitor
EP2254907A1 (de) *	2008-03-17	2010-12-01	F. Hoffmann-La Roche AG	Kristalle mit lxr-liganden-bindungsdomäne
BRPI0912267A2 (pt) *	2008-05-23	2015-10-13	Amira Pharmaceuticals Inc	sal farmaceuticamente aceitável, composição farmacêutica, artigo de fabricação, métodos para tratar asma, rinite alérgica, doença, lesões gástricas e dor, métodos para prevenir broncoconstrição e rinite alérgica, uso de um sal farmaceuticamente aceitável, e, processo para a preparação de um sal farmaceuticamente aceitável.
TW201006821A (en)	2008-07-16	2010-02-16	Bristol Myers Squibb Co	Pyridone and pyridazone analogues as GPR119 modulators
US8546431B2 (en)	2008-10-01	2013-10-01	Panmira Pharmaceuticals, Llc	5-lipoxygenase-activating protein (FLAP) inhibitors
MX2012011460A (es)	2010-04-08	2012-11-23	Squibb Bristol Myers Co	Analogos de pirimidinilpiperidiniloxipiridinona como moduladores de gpr119.
EA201270778A1 (ru)	2010-05-06	2013-04-30	Бристол-Майерс Сквибб Компани	Бициклические гетероарильные аналоги в качестве модуляторов рецептора gpr119
WO2011140161A1 (en)	2010-05-06	2011-11-10	Bristol-Myers Squibb Company	Benzofuranyl analogues as gpr119 modulators
EP2665707B1 (de)	2011-01-20	2017-01-18	Merck Sharp & Dohme Corp.	Mineralkortikoid-rezeptorantagonisten
EP2850073B1 (de)	2012-05-16	2017-07-19	Bristol-Myers Squibb Company	Pyrimidinylpiperidinyloxypyridon-analoga als gpr119-modulatoren
MX375256B (es)	2012-07-13	2025-03-06	Gtx Inc	Metodo para tratar canceres de mama positivos a receptor de androgeno (ar) con modulador de receptor de androgeno selectivo (sarms).
US10314807B2 (en)	2012-07-13	2019-06-11	Gtx, Inc.	Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10987334B2 (en)	2012-07-13	2021-04-27	University Of Tennessee Research Foundation	Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US9969683B2 (en)	2012-07-13	2018-05-15	Gtx, Inc.	Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10258596B2 (en)	2012-07-13	2019-04-16	Gtx, Inc.	Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9744149B2 (en)	2012-07-13	2017-08-29	Gtx, Inc.	Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9622992B2 (en)	2012-07-13	2017-04-18	Gtx, Inc.	Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
EP2970119B1 (de) *	2013-03-14	2021-11-03	Merck Sharp & Dohme Corp.	Neuartige indolderivate als antidiabetika
US9580422B2 (en)	2013-10-22	2017-02-28	Bristol-Myers Squibb Company	Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
CA2939120A1 (en)	2014-01-10	2015-07-16	Rgenix, Inc.	Lxr agonists and uses thereof
CA3010883A1 (en)	2016-01-11	2017-07-20	The Rockefeller University	Methods for the treatment of myeloid derived suppressor cells related disorders
CN106187899B (zh) *	2016-06-28	2019-07-16	绍兴文理学院	一种氟代氮杂芳烃的合成方法
WO2018017910A1 (en)	2016-07-22	2018-01-25	Bristol-Myers Squibb Company	Glucokinase activators and methods of using same
EP3713575A4 (de)	2017-11-21	2021-08-25	Rgenix, Inc.	Polymorphe und ihre verwendung
TWI748194B (zh)	2018-06-28	2021-12-01	德商菲尼克斯Ｆｘｒ有限責任公司	含有雙環核心部分之新穎lxr調節劑
US20200085810A1 (en)	2018-07-26	2020-03-19	Hoffmann-La Roche Inc.	Compounds for use in treating kidney disorders
CN110305141B (zh)	2019-07-18	2022-01-11	深圳市三启药物开发有限公司	一种螺(3,3’-异丙基吡咯烷氧化吲哚)类肝x受体调节剂及其制备方法和应用
JP7689964B2 (ja)	2019-12-13	2025-06-09	インスピルナ，インコーポレーテッド	金属塩及びその使用
CN115028655B (zh) *	2022-05-20	2024-01-16	上海大学	一种2-三氟甲基-3-碘-吲哚类化合物及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4251659A (en) *	1977-12-22	1981-02-17	E. I. Du Pont De Nemours And Company	Polyfluorohydroxyisopropyl-heterocyclic compounds
GR63361B (en) *	1976-06-24	1979-10-22	Du Pont	Preparation process of antihypertensive hexafluorohydroxyisopropyl bicyclic and tricyclic carbostyrils
DK151884C (da) *	1979-03-07	1988-06-13	Pfizer	Analogifremgangsmaade til fremstilling af 3-(1-imidazolylalkyl)indolderivater eller farmaceutisk acceptable syreadditionssalte deraf
JPH0995482A (ja)	1995-09-29	1997-04-08	Shionogi & Co Ltd	α−置換酢酸を有する複素環誘導体、その製造用中間体ならびにそれを含有する農薬
WO1997019311A1 (en)	1995-11-17	1997-05-29	Form Rite	Bypass fitting for a transmission fluid cooler
DE60211891T2 (de)	2001-05-15	2007-05-24	F. Hoffmann-La Roche Ag	Carbonsäure-substituierte oxazol-derivate zur verwendung als ppar-alpha und -gamma aktivatoren zur behandlung von diabetes
US6472386B1 (en)	2001-06-29	2002-10-29	Kowa Co., Ltd.	Cyclic diamine compound with 5-membered ring groups
GB0216224D0 (en)	2002-07-12	2002-08-21	Glaxo Group Ltd	Compounds

2005
- 2005-04-26 DK DK05751959T patent/DK1756096T3/da active
- 2005-04-26 BR BRPI0510599-4A patent/BRPI0510599A/pt not_active IP Right Cessation
- 2005-04-26 AU AU2005238176A patent/AU2005238176B2/en not_active Ceased
- 2005-04-26 CN CNA2005800142069A patent/CN1950365A/zh active Pending
- 2005-04-26 PL PL05751959T patent/PL1756096T3/pl unknown
- 2005-04-26 AT AT05751959T patent/ATE439357T1/de active
- 2005-04-26 KR KR1020067023014A patent/KR100893449B1/ko not_active Expired - Fee Related
- 2005-04-26 MX MXPA06012683A patent/MXPA06012683A/es active IP Right Grant
- 2005-04-26 RU RU2006142746/04A patent/RU2368612C2/ru not_active IP Right Cessation
- 2005-04-26 EP EP05751959A patent/EP1756096B1/de not_active Expired - Lifetime
- 2005-04-26 JP JP2007511949A patent/JP4682192B2/ja not_active Expired - Fee Related
- 2005-04-26 SI SI200530765T patent/SI1756096T1/sl unknown
- 2005-04-26 NZ NZ550447A patent/NZ550447A/en not_active IP Right Cessation
- 2005-04-26 PT PT05751959T patent/PT1756096E/pt unknown
- 2005-04-26 WO PCT/EP2005/004454 patent/WO2005105791A1/en not_active Ceased
- 2005-04-26 ES ES05751959T patent/ES2329489T3/es not_active Expired - Lifetime
- 2005-04-26 DE DE602005015962T patent/DE602005015962D1/de not_active Expired - Lifetime
- 2005-04-26 CA CA2564563A patent/CA2564563C/en not_active Expired - Fee Related
- 2005-04-26 HR HR20090533T patent/HRP20090533T1/xx unknown
- 2005-04-27 US US11/115,942 patent/US7173048B2/en not_active Expired - Fee Related
- 2005-04-28 MY MYPI20051897A patent/MY139571A/en unknown
- 2005-04-29 TW TW094113966A patent/TWI287537B/zh not_active IP Right Cessation
- 2005-04-29 AR ARP050101717A patent/AR049497A1/es unknown
2006
- 2006-10-19 IL IL178767A patent/IL178767A0/en unknown
- 2006-10-25 ZA ZA200608886A patent/ZA200608886B/en unknown
- 2006-11-29 NO NO20065503A patent/NO20065503L/no not_active Application Discontinuation
- 2006-12-11 US US11/636,925 patent/US7485652B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DK1756096T3 (da)	2009-10-26
NO20065503L (no)	2007-01-24
HRP20090533T1 (hr)	2009-11-30
EP1756096A1 (de)	2007-02-28
IL178767A0 (en)	2007-02-11
DE602005015962D1 (de)	2009-09-24
RU2006142746A (ru)	2008-06-10
WO2005105791A1 (en)	2005-11-10
KR100893449B1 (ko)	2009-04-17
NZ550447A (en)	2010-06-25
JP4682192B2 (ja)	2011-05-11
MXPA06012683A (es)	2007-01-16
CA2564563C (en)	2011-07-05
PT1756096E (pt)	2009-10-16
AR049497A1 (es)	2006-08-09
AU2005238176A1 (en)	2005-11-10
JP2007536300A (ja)	2007-12-13
US7173048B2 (en)	2007-02-06
CA2564563A1 (en)	2005-11-10
PL1756096T3 (pl)	2010-01-29
TWI287537B (en)	2007-10-01
AU2005238176B2 (en)	2008-11-27
US20070099916A1 (en)	2007-05-03
US20050245515A1 (en)	2005-11-03
US7485652B2 (en)	2009-02-03
ZA200608886B (en)	2008-06-25
BRPI0510599A (pt)	2007-11-20
ES2329489T3 (es)	2009-11-26
SI1756096T1 (sl)	2009-10-31
EP1756096B1 (de)	2009-08-12
KR20070008678A (ko)	2007-01-17
RU2368612C2 (ru)	2009-09-27
TW200606147A (en)	2006-02-16
CN1950365A (zh)	2007-04-18
MY139571A (en)	2009-10-30

Legal Events

Date

Code

Title

Description

2010-04-15

UEP

Publication of translation of european patent specification

Ref document number: 1756096

Country of ref document: EP

Publication	Publication Date	Title
ATE439357T1 (de)	2009-08-15	Indolylderivate als liver-x-rezeptormodulatoren
CY2017008I1 (el)	2017-11-14	Νεες ενωσεις ως διαμορφωτες υποδοχεα οπιοειδων
ATE545631T1 (de)	2012-03-15	N-(2-benzyl)-2-phenylbutanamide als androgenrezeptormodulatoren
DE602007006531D1 (de)	2010-06-24	Pyrazin-2-carboxamid-derivate als cb2-rezeptormodulatoren
ATE510831T1 (de)	2011-06-15	Hydrierte benzoäcüthiophenderivate als immunmodulatoren
ATE413874T1 (de)	2008-11-15	Neue thiophen-derivate als sphingosin-1-phosphat- 1-rezeptorantagonisten
ATE537157T1 (de)	2011-12-15	Substituierte phenoxy-n-alkylierte thiazoledindione als östrogenassoziierte rezeptor-alpha-modulatoren
DE602005018190D1 (de)	2010-01-21	Als modulatoren des dopamin-d3-rezeptors geeignete azabicycloä3.1.0ühexanderivate
ATE523195T1 (de)	2011-09-15	Neue thiophen-derivate als sphingosin-1-phosphat- 1-rezeptorantagonisten
ATE513827T1 (de)	2011-07-15	Oxyindol-derivate als 5ht4-rezeptor-agonisten
ATE394391T1 (de)	2008-05-15	Indolderivate als histaminrezeptorantagonisten
ATE529429T1 (de)	2011-11-15	Tricyclische spiroderivate als crth2-modulatoren
ATE387202T1 (de)	2008-03-15	Pyrrolidinderivate als histaminrezeptor-liganden
ATE421511T1 (de)	2009-02-15	Indol-3-carbonyl-spiro-piperidinderivate als antagonisten des v1a-rezeptors
DE602004014772D1 (de)	2008-08-14	Pyrrol-2,5-dithionderivate als modulatoren des liver-x-rezeptors
DE602004014773D1 (de)	2008-08-14	Pyrrol-2,5-dionderivate als modulatoren des liver-x-rezeptors
EP1890696A4 (de)	2010-05-05	Als orl-1-rezeptormodulatoren geeignete neue 3-spirocyclische indolylderivate
ZA200609234B (en)	2008-08-27	Substituted azeplne derivatives as serotonin receptor modulators
ATE525354T1 (de)	2011-10-15	Benzofuranderivate als selektive androgenrezeptormodulatoren (sarms)
ATE472544T1 (de)	2010-07-15	Als via-rezeptor-antagonisten verwendbare indole
EP1751115A4 (de)	2010-10-20	Theramuteinmodulatoren
ATE396998T1 (de)	2008-06-15	Tetrazyklische imidazobenzodiazepine als gaba- rezeptormodulatoren
DE602006003666D1 (de)	2008-12-24	Indol-3-ylcarbonylpiperidinbenzimidazolderivate als v1a-rezeptorantagonisten
DE602006015186D1 (de)	2010-08-12	Oxindole als kinaseinhibitoren
DE602006008002D1 (de)	2009-09-03	Benzofuranylderivate als 5-ht6-rezeptorinhibitoren